Publication Relating to a Transparency Notification

REGULATED INFORMATION Publication Relating to a Transparency Notification Mont-Saint-Guibert (Belgium), July 27, 2023, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a rectification of an earlier transparency notification. On July 25, […]

Publication Relating to a Transparency Notification Read More

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023

Mont-Saint-Guibert, Belgium – July 27, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter of 2023 […]

Nyxoah to Release Second Quarter 2023 Financial Results on August 8, 2023 Read More

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages TriplePoint Venture Growth BDC Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TPVG

NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TriplePoint Venture Growth BDC Corp. (NYSE: TPVG) between March 4, 2020 and May 1, 2023, both dates inclusive (the “Class Period”), of the important August 15, 2023 lead plaintiff deadline. SO WHAT: […]

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages TriplePoint Venture Growth BDC Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TPVG Read More

Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference

Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference Mont-Saint-Guibert, Belgium – July 27, 2023, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company […]

Nyxoah to Participate in the 43rd Canaccord Genuity Growth Conference Read More